Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art.

Introduction: Gastric adenocarcinoma (GAC) remains a prevalent cancer worldwide and its incidence is increasing in South America. The heterogenous nature of GAC makes advances in management challenging.

Areas Covered: Despite challenges, recent therapeutic targets are individualizing treatment.